Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Laryngoscope. 2015 Dec 15;126(10):2410–2418. doi: 10.1002/lary.25799

Table 2.

Relationship between fibroblast MCT4 and prognostic biomarkers.

Papillary Thyroid Carcinoma (n=46)
Low stromal MCT4 High stromal MCT4 p-value
No adenopathy 100% (10/10) 37% (17/36) 0.001
No ETE 100% (10/10) 61% (22/36) 0.020
Low ATA risk 100% (10/10) 58% (21/36) 0.0009
Low AMES risk 100% (10/10) 39% (14/36) 0.020